Express News | Shanghai Pharmaceutical: Terminating clinical trials and subsequent development of three R&D projects including the I010 project
Shanghai Pharmaceutical (601607.SH): New specifications for injectable parecoxib sodium have been approved
Gelonghui, April 30 | Shanghai Pharmaceutical (601607.SH) announced that its wholly-owned subsidiary Shangyao Dongying (Jiangsu) Pharmaceutical Co., Ltd., received the “Drug Supplement Application Approval Notice” issued by the State Drug Administration, and the new specification of the drug, 40 mg, was approved. Injectable parecoxib sodium is mainly used for short-term treatment of pain after surgery. It was first developed by Pfizer and marketed in Europe in 2002.
Express News | Shanghai Pharmaceutical: Terminating clinical trials and subsequent development of the I010, B002 and B003 projects
Shanghai Pharmaceuticals Holding's Q1 Profit Rises 2% as Revenue Grows 6%
Shanghai Pharmaceuticals Holding's (SHA:601607, HKG:2607) attributable profit rose 1.62% year over year to 1.54 billion yuan in the first quarter from 1.52 billion yuan, according to separate filings
Featured announcements | The total amount of AIA share repurchase plans increased to US$12 billion; Sinopec's net profit for the first quarter decreased 8.9% year-on-year
China Shenhua's net profit for the first quarter was 15.884 billion yuan, a year-on-year decrease of 14.7%; China Life Insurance's net profit for the first quarter was 20.644 billion yuan, a decrease of 9.3% year-on-year.
Express News | Shanghai Pharmaceutical: It is intended to issue various short-term debt financing products and medium- to long-term debt financing products with a balance equal to RMB 15 billion.
Shanghai Pharmaceutical (02607) plans to apply for the issuance of various short-term debt financing products and medium- to long-term debt financing products
Shanghai Pharmaceutical (02607) issued an announcement. The company plans to apply for a distribution balance of not more than RMB 15 billion worth of all types...
Shanghai Pharmaceutical (02607.HK) net profit of 1,542 billion yuan in the first quarter increased 1.62% year-on-year
Gelonghui, April 26 | Shanghai Pharmaceutical (02607.HK) announced that in the first quarter of 2024, during the reporting period, the company's main business grew steadily, achieving operating revenue of 70.153 billion yuan (currency is RMB, same below), an increase of 5.93% over the previous year. Among them, the pharmaceutical industry achieved sales revenue of 6.944 billion yuan, a year-on-year decrease of 10.98%; the pharmaceutical business achieved sales revenue of 63.209 billion yuan, an increase of 8.19% over the previous year. During the reporting period, the company achieved net profit attributable to shareholders of listed companies of 1,542 billion yuan, an increase of 1.62% over the previous year. Among them, the industrial business contributed profit
Express News | Shanghai Pharmaceutical: Net profit from mother in the first quarter was 1,542 billion yuan, up 1.62% year-on-year
上海醫藥:2024年第一季度報告
上海醫藥:2023 年年報
Hong Kong Stock Concept Tracking | The 2024 trend of mergers and acquisitions of pharmaceutical distribution companies is expected to further accelerate leading state-owned enterprises to attract attention (with concept stocks)
The trend of mergers and acquisitions of domestic pharmaceutical distribution companies is expected to accelerate further, and the concentration of leaders may further increase
Featured announcements | Zijin Mining's Q1 net profit increased 15% year over year; Bubble Mart's overseas revenue increased by more than 240% in the first quarter
China Mobile's Q1 net profit increased 5.5% year over year to 29.6 billion yuan; Chabaidao's IPO was priced at HK$17.50 per share, with a net raise of HK$2,463 billion.
Express News | Shanghai Pharmaceutical: WST03 preparation clinical trial application accepted
Damo: Target price for Shanghai Pharmaceutical (02607) “gain” rating reduced to HK$17
DamocaSea Pharmaceuticals (02607) lowered its 2024-2030 profit forecast by 2%-9%.
Shanghai Pharmaceutical (02607.HK) held a board meeting on April 26 to approve the first quarter results
Gelonghui, April 16 | Shanghai Pharmaceutical (02607.HK) announced that the board of directors meeting will be held on April 26, 2024 (Friday) to approve (among other things) the first quarter results of the company and its subsidiaries for the three months ended March 31, 2024 and their announcements.
上海醫藥:董事會會議通告
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Southwest Securities released a research report on April 11 stating that it gave Shanghai Pharmaceutical (601607.SH) a purchase rating. The main reasons for the rating include: 1) incident: the company released its 2023 annual report; 2) pharmaceutical bu
Southwest Securities released a research report on April 11 stating that it gave Shanghai Pharmaceutical (601607.SH) a purchase rating. The main reasons for the rating include: 1) incident: the company released its 2023 annual report; 2) pharmaceutical business: accelerating the layout of commercial network coverage and continuing to consolidate its leading position; 3) pharmaceutical industry: continuing to promote the cultivation strategy of large varieties of traditional Chinese medicine around the big variety strategy; 4) the innovation pipeline has entered the harvest period, and the market potential is huge. (Mainichi Keizai Shimbun)
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
No Data